Therapy News and Research

RSS

Levetiracetam to be tested for seizure management in malaria endemic regions

Michigan State University researchers, with the help of a groundbreaking medical device, are starting a clinical trial in Africa they hope will provide relief for the hundreds of thousands of children who survive cerebral malaria but are left stricken with epilepsy or other neurologic disorders.

2 May 2012

Grape-derived compound may prevent neurodegenerative disorders involving tau neuropathology

Researchers at Mount Sinai School of Medicine have gained insight into the mechanism by which a pathological brain protein called tau contributes to the progression of Alzheimer's disease (AD) and other neurodegenerative disorders. This finding, published in the most recent issue of the Journal of Biological Chemistry, may provide the basis for future investigations on how to prevent tau from damaging brain circuits involved in cognitive function.

2 May 2012

Biosynthetic polyphenol may improve cognitive function in Alzheimer's disease patients

Mount Sinai School of Medicine researchers have succeeded in developing a biosynthetic polyphenol that improves cognitive function in mice with Alzheimer's disease (AD). The findings, published in a recent issue of the Journal of Neuroscience, provide insight in determining the feasibility of biosynthetic polyphenols as a possible therapy for AD in humans, a progressive neurodegenerative disease for which there is currently no cure.

2 May 2012

Lower rate of reintubation observed in infants receiving SURFAXIN

Discovery Laboratories, Inc. today announced the presentation of a new pharmacoeconomic analysis demonstrating that the lower rate of reintubation previously reported in infants treated with SURFAXIN, when compared with infants treated with Curosurf® and Survanta®, the current global market leading surfactants, also resulted in a potential hospital cost savings of $160,000 to $252,000 per 100 infants.

2 May 2012

Novo Nordisk granted exclusive rights to Caisson's heparosan-based drug delivery technology

Caisson Biotech, L.L.C., a biopharmaceutical company with a patented heparosan-based drug delivery technology, announced today that it has entered into a Development and License Agreement with Novo Nordisk A/S, a global healthcare company and leader in diabetes care.

From Novo Nordisk 2 May 2012

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2012 results.

2 May 2012

JLGTD to publish results from Cutaneous Lysate study on vulvodynia

The results from Dr. Gilbert G. Donders' MD, PhD study testing Cutaneous Lysate in women suffering from vulvar pain has been accepted for publication in the Journal of Lower Genital Tract Disease.

2 May 2012

Ultragenyx reports results from UX001 Phase 1 study on HIBM

Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration

2 May 2012

Accelerated partial breast irradiation therapy increases risk for subsequent mastectomy

Accelerated partial breast irradiation (APBI) brachytherapy, the localized form of radiation therapy growing increasingly popular as a treatment choice for women with early-stage breast cancer, is associated with higher rate of later mastectomy, increased radiation-related toxicities and post-operative complications, compared to traditional whole breast irradiation (WBI), according to researchers from The University of Texas MD Anderson Cancer Center.

2 May 2012

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2012.

2 May 2012

FDA approves Protalix, Pfizer’s ELELYSO for treatment of type 1 Gaucher disease

Pfizer Inc. and Protalix BioTherapeutics, Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.

2 May 2012

Endocrine Society and its Hormone Health Network release ‘Menopause Map’

Women going through menopause now have a first-of-its-kind interactive guide to help them better understand their menu of treatment options, including whether hormone therapy may be right for them. The Endocrine Society and its Hormone Health Network today released the "Menopause Map," an online tool to help women and their doctors discuss which hormonal and non-hormonal treatment options would be most effective and safe to relieve the sometimes debilitating symptoms of menopause.

2 May 2012

Synthetic stool transplant for C. difficile treatment

A synthetic mixture of intestinal bacteria could one day replace stool transplants as a treatment for Clostridium difficile (C. difficile). C. difficile is a toxin-producing bacteria that can overpopulate the colon when antibiotics eradicate other, naturally protective bacteria living there.

2 May 2012

ASNTR honors UTMSH, MSU scientists with 2012 Sanberg awards

At the 19th Annual Conference of the American Society of Neural Therapy and Repair (ASNTR), held April 26 - 28 in Clearwater Beach, Florida, the ASNTR awarded The 2012 Bernard Sanberg Memorial Award for Brain Repair to Timothy J. Collier, PhD, professor of translational science and molecular medicine at Michigan State University and director of the Udall Center of Excellence in Parkinson's Disease Research at Michigan State University and the University of Cincinnati. ASNTR also presented The Molly and Bernard Sanberg Memorial Award to Sean I. Savitz, MD, associat

2 May 2012

Thoratec first quarter revenues increase 27% to $126.8M

Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that revenues for the first quarter of 2012 were $126.8 million, an increase of 27% versus revenues of $99.5 million in the same period a year ago.

2 May 2012

World behind on pledge to reduce HIV/AIDS infections, improve treatment, U.N. report says

"The world is falling behind in its pledge to reduce HIV/AIDS infections and improve treatment, especially in sub-Saharan Africa, according to a U.N. report released Monday" by U.N. Secretary-General Ban Ki-moon, the Associated Press reports.

2 May 2012

NIH study indicates safety of anti-HIV drug tenofovir during pregnancy

Infants born to women who used the anti-HIV drug tenofovir as part of an anti-HIV drug regimen during pregnancy do not weigh less at birth and are not of shorter length than infants born to women who used anti-HIV drug regimens that do not include tenofovir during pregnancy, according to findings from a National Institutes of Health network study.

2 May 2012

USC, Align close previously announced merger

Align Networks, Inc., a leading provider of workers' compensation physical medicine programs, and Universal SmartComp, a nationwide provider of physical medicine services, today announced that they have closed their previously announced merger.

2 May 2012

CHR-3996 pill shows promise against advanced cancers

Scientists have shown that a brand new type of cancer pill that exploits the emerging field of epigenetics is safe for human use, according to a Phase I trial reported today in Clinical Cancer Research.

2 May 2012

Vessix V2 Renal Denervation System for hypertension receives CE Mark approval

Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has received Conformite Europeenne (CE) Mark approval for its V2 Renal Denervation System for the treatment of hypertension.

2 May 2012